TD Cowen analyst Brendan Smith initiated coverage of West Pharmaceutical (WST) with a Buy rating and $350 price target West sits at the nexus of multiple, sector-wide trends – including injectable biologics, GLP-1s and expanding regulatory demand – that have helped the company evolve from a supplier of standard drug delivery components towards high-value products with higher gross margins, the analyst tells investors. The mix shift to higher value products should sustainably grow revenue and margins long term, the analyst contends.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WST:
- West Pharmaceutical removed from ‘Tactical Outperform’ list at Evercore ISI
- West Pharmaceutical price target raised to $325 from $275 at Barclays
- West Pharmaceutical price target raised to $370 from $310 at BofA
- West Pharmaceutical price target raised to $355 from $320 at UBS
- West Pharmaceutical price target raised to $345 from $305 at Deutsche Bank